Secukinumab in patients with moderate to severe hidradenitis suppurativa based on prior biologic exposure: An efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials

CONCLUSIONS: Regardless of prior biologic exposure, secukinumab was efficacious in improving signs and symptoms of HS. This finding positions secukinumab as the first option in patients who are biologic-naïve, as well as in patients who have previously been treated with other biologic therapy, based on individual patient needs.TRIAL REGISTRATION: SUNSHINE (NCT03713619) and SUNRISE (NCT03713632).PMID:38470171 | DOI:10.1093/bjd/ljae098

Source: The British Journal of Dermatology - March 12, 2024 Category: Dermatology Authors: Christos C Zouboulis Thierry Passeron David Pariser Magdalena B Wozniak Xianjun Li Lorenz Uhlmann Iryna Lobach Angela Llobet Martinez Shoba Ravichandran Ivette Alarcon Annamaria Offidani Maryam S Alam Pedro Mendes-Bastos Source Type: research